Highlights Formosa Pharmaceuticals, Inc.

Equities

6838

TW0006838006

End-of-day quote Taipei Exchange Other stock markets 03:30:00 03/06/2024 am IST			5-day change	1st Jan Change
53.3 ^TWD	-0.56%		-0.37%	+6.71%

09/05	Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	CI
07/03	Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	09/05	CI
Formosa Pharmaceuticals, Inc. Announces FDA Approval for the NDA of A Global Innovative Hormone Nanosuspension Eye Drops	07/03	CI
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery	05/03	CI
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03	RE
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02	CI
Formosa Pharmaceuticals Announces Licensing Agreement with Cristália, for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	26/01	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/12	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery	05/23/05	CI
Formosa Pharmaceuticals, Inc. Announces Phase III Clinical Study of a Global Innovative Hormone Nanosuspension Eye Drops Successfully Reached Clinical Endpoint	11/23/11	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	21/23/21	CI
Formosa Pharmaceuticals, Inc. Enter into A Collaboration Agreement with Eyenovia, Inc. for the Development of Novel Ophthalmic Therapeutics	15/23/15	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	11/22/11	CI
Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. Announce Successful Top-Line Results from CPN-302 for the Treatment of Inflammation and Pain after Cataract Surgery	09/22/09	CI
Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery	12/22/12	CI
Formosa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	16/22/16	CI
HCmed Innovations, Formosa Laboratories, and Formosa Pharmaceuticals Signs MoU to Form A Global CDMO for Inhalation Treatment Drugs	07/22/07	CI
China Grand Pharmaceutical and Healthcare Holdings Limited Announces That the Group Recently Reached an Exclusive Product Licensing Agreement with Formosa Pharmaceuticals, Inc	03/21/03	CI
Formosa Pharmaceuticals, Inc. completed the acquisition of Activus Pharma Co., Ltd. from Sosei Group Corporation.	10/17/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Formosa Pharmaceuticals, Inc.

Equities

6838

TW0006838006

Highlights

Filters